Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020 : Episode 12

Video

November 24, 2020

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Author(s):

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD

EP: 1.Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP: 2.OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP: 3.OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP: 4.Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP: 5.Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP: 6.Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP: 7.OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP: 8.OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP: 9.Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP: 10.Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP: 11.Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP: 12.Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP: 13.CLARITY Extension Trial: Disability Improvement With Cladribine

EP: 14.COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP: 15.Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos

Esther Labib-Kiyarash, MSHA, CPHQ

Justin Martello, MD

William Ondo, MD

Jennifer Corcoran, MD

Marcia Pasqualini, PhD

Anissa Mitchell, LCSW

Daniel Irizarry, MD

Gabrielle Macaron, MD

Agne Straukiene, MD

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.